WINSUN BIO(BJ:839729)2023-04-19 16:00Financial Performance - The company's operating revenue for 2022 was CNY 348,717,555.84, a decrease of 4.07% compared to CNY 363,525,642.57 in 2021[27]. - The net profit attributable to shareholders for 2022 was CNY 86,035,881.94, down 5.81% from CNY 91,342,217.51 in 2021[27]. - The total assets at the end of 2022 amounted to CNY 868,912,246.16, reflecting a growth of 7.38% from CNY 809,181,608.59 at the end of 2021[28]. - The total liabilities increased by 66.45% to CNY 172,771,172.59 in 2022, compared to CNY 103,796,628.70 in 2021[28]. - The company's cash flow from operating activities for 2022 was CNY 69,106,539.37, a decline of 31.38% from CNY 100,703,991.33 in 2021[30]. - The gross profit margin for 2022 was 62.53%, down from 67.43% in 2021[27]. - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 12.38% for 2022, compared to 13.32% in 2021[27]. - The company reported a basic earnings per share of CNY 0.32 for 2022, a decrease of 3.03% from CNY 0.33 in 2021[27]. - The company reported a total non-recurring profit and loss of ¥10,954,801.97 in 2022, an increase of 55.5% compared to ¥7,074,154.63 in 2021[36]. - The company distributed cash dividends totaling 76.36 million yuan based on a plan to distribute 2.8 yuan per 10 shares[55]. Research and Development - The company holds 24 invention patents and 9 utility model patents, with 19 new veterinary drug certificates obtained[12]. - The company has developed two new veterinary vaccines, but market acceptance is currently low, leading to potential revenue risks[13]. - Research and development expenses amounted to 25.38 million yuan, representing 7.28% of operating revenue, with new veterinary drug certificates and patents obtained during the period[51]. - The company is developing a new multi-valent inactivated vaccine for poultry, aiming to enhance immune protection efficiency and product practicality, with the goal of obtaining new veterinary drug certificates and achieving industrialization[100]. - The company is working on a new bivalent inactivated vaccine for swine influenza (H1N1 and H3N2), utilizing MDCK cell culture, which is expected to contribute positively to the development of swine influenza vaccines[100]. - The company is developing a heat-resistant inactivated vaccine for swine diseases, which aims to simplify immunization procedures and reduce stress and infection risks, thereby improving immune efficacy[100]. - The company is advancing the development of a carbon nanotube-based subunit vaccine for the bass virus, addressing urgent needs in the aquaculture industry and aiming for industrialization[100]. - The company is establishing a gene editing technology and recombinant protein expression techniques to create safer and more effective vaccines against major animal diseases[102]. - The company is focusing on the development of multi-valent vaccines to optimize immunization programs and reduce costs for livestock farmers[117]. Market and Industry Risks - The company faces risks related to fluctuations in the downstream livestock and poultry farming industry, which could impact vaccine demand and overall performance[11]. - The company’s main products include high pathogenic avian influenza vaccines, which are subject to national procurement policy changes[11]. - The company faces risks related to the sustainability of cooperative research and technology introduction partnerships[13]. - The company has implemented effective measures to mitigate environmental impact, but risks remain if compliance with environmental standards is not maintained[13]. - The company’s product demand is closely tied to the livestock industry, with potential performance fluctuations due to natural disasters or major animal disease outbreaks[127]. - The company is a designated producer of inactivated avian influenza vaccines, and changes in national procurement policies could adversely affect profitability[128]. Corporate Governance and Compliance - The company has a total share capital of 273,350,000 shares, with 80,244,567 shares (29.36%) being unrestricted and 193,105,433 shares (70.64%) being restricted[174]. - The board of directors consists of 9 members, with no controlling shareholder or actual controller present[199]. - The company has a supervisory board consisting of 3 members[198]. - The company has a total of 3 independent directors, ensuring governance and oversight[198]. - The company has not reported any significant legal disputes or conflicts of interest involving its directors and senior management during the reporting period[162]. - The commitments made by the company and its major shareholders regarding the avoidance of related party transactions are being fulfilled[159]. - The company has confirmed that all commitments made prior to its listing on the New Third Board are being actively fulfilled[154]. Environmental and Social Responsibility - The company reported a wastewater discharge of 61,627.03 tons per year, with treatment systems in place to manage this waste[116]. - The company donated RMB 36,000 worth of epidemic prevention supplies to the authorities in Yanbian, Jilin Province, during the reporting period[115]. - The company has implemented strict biosecurity measures and management systems to mitigate the risk of biological safety incidents during vaccine production[132]. - Environmental protection measures are in place to comply with regulations, but failure to adhere to increasing standards could lead to operational and reputational damage[141]. Shareholder Information - The top three shareholders of Guangdong Yongshun Biological Pharmaceutical Co., Ltd. are Modern Agricultural Group (39.0638%), Guangdong Agricultural Asset Management Co., Ltd. (19.7081%), and the Animal Health Research Institute of the Guangdong Academy of Agricultural Sciences (11.2676%)[181]. - The total number of shares held by the top ten shareholders is 221,714,894, representing 81.1103% of the total shares[178]. - The company has a total of 3,640 common shareholders, indicating a diverse shareholder base[174]. - The company has ongoing commitments from major shareholders to avoid related party transactions and fund occupation, which are currently being fulfilled[153]. Financial Management - The company has secured loans totaling CNY 20,000,000.00 from China Construction Bank at an interest rate of 3% and CNY 9,900,000.00 from Agricultural Bank of China at the same interest rate[192]. - The company has applied for commercial acceptance bill discount financing totaling CNY 62,313,700.00, with an outstanding balance of CNY 27,542,200.00 as of the reporting period end[193]. - The company has complied with regulatory requirements regarding the management and use of raised funds, with no violations reported[188]. - The company has not changed the intended use of the raised funds, and all funds have been used as planned[189].